Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Gram-negative bacterial molecules associate with Alzheimer disease pathology.

Zhan X, Stamova B, Jin LW, DeCarli C, Phinney B, Sharp FR.

Neurology. 2016 Nov 29;87(22):2324-2332. Epub 2016 Oct 26.

2.

Myelin basic protein associates with AβPP, Aβ1-42, and amyloid plaques in cortex of Alzheimer's disease brain.

Zhan X, Jickling GC, Ander BP, Stamova B, Liu D, Kao PF, Zelin MA, Jin LW, DeCarli C, Sharp FR.

J Alzheimers Dis. 2015;44(4):1213-29. doi: 10.3233/JAD-142013.

3.

Inflammation Combined with Ischemia Produces Myelin Injury and Plaque-Like Aggregates of Myelin, Amyloid-β and AβPP in Adult Rat Brain.

Zhan X, Cox C, Ander BP, Liu D, Stamova B, Jin LW, Jickling GC, Sharp FR.

J Alzheimers Dis. 2015;46(2):507-23. doi: 10.3233/JAD-143072.

4.

Lipopolysaccharide Associates with Amyloid Plaques, Neurons and Oligodendrocytes in Alzheimer's Disease Brain: A Review.

Zhan X, Stamova B, Sharp FR.

Front Aging Neurosci. 2018 Feb 22;10:42. doi: 10.3389/fnagi.2018.00042. eCollection 2018. Review.

5.

Characteristics of aquaporin expression surrounding senile plaques and cerebral amyloid angiopathy in Alzheimer disease.

Hoshi A, Yamamoto T, Shimizu K, Ugawa Y, Nishizawa M, Takahashi H, Kakita A.

J Neuropathol Exp Neurol. 2012 Aug;71(8):750-9. doi: 10.1097/NEN.0b013e3182632566.

PMID:
22805778
6.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2010 Jan;117(1):85-96. doi: 10.1007/s00702-009-0314-x. Epub 2009 Oct 13.

7.

Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity.

Collins-Praino LE, Francis YI, Griffith EY, Wiegman AF, Urbach J, Lawton A, Honig LS, Cortes E, Vonsattel JP, Canoll PD, Goldman JE, Brickman AM.

Acta Neuropathol Commun. 2014 Aug 17;2:83. doi: 10.1186/s40478-014-0083-0.

8.

Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain.

Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A.

J Alzheimers Dis. 2014;40(2):297-308. doi: 10.3233/JAD-132081.

9.

An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.

Kannan P, Schain M, Kretzschmar WW, Weidner L, Mitsios N, Gulyás B, Blom H, Gottesman MM, Innis RB, Hall MD, Mulder J.

J Cereb Blood Flow Metab. 2017 Jun;37(6):2062-2075. doi: 10.1177/0271678X16660984. Epub 2016 Jan 1.

10.

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A.

Neurology. 2009 Apr 28;72(17):1487-94. doi: 10.1212/WNL.0b013e3181a2e8d0. Epub 2009 Apr 1.

PMID:
19339712
11.

Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.

Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L.

Neuron. 2006 Sep 21;51(6):703-14.

12.

Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation?

Asti A, Gioglio L.

J Alzheimers Dis. 2014;39(1):169-79. doi: 10.3233/JAD-131394.

PMID:
24150108
13.
14.

[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.

Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B.

Neurochem Int. 2009 May-Jun;54(5-6):347-57. doi: 10.1016/j.neuint.2008.12.016. Epub 2008 Dec 30.

PMID:
19162107
15.

Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques.

Pensalfini A, Albay R 3rd, Rasool S, Wu JW, Hatami A, Arai H, Margol L, Milton S, Poon WW, Corrada MM, Kawas CH, Glabe CG.

Neurobiol Dis. 2014 Nov;71:53-61. doi: 10.1016/j.nbd.2014.07.011. Epub 2014 Aug 1.

16.
17.

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease.

Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K.

Acta Neuropathol. 2010 Aug;120(2):185-93. doi: 10.1007/s00401-010-0690-1. Epub 2010 Apr 24.

18.

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3632-7. Epub 2004 Feb 20.

19.

K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice.

Zhang YH, Mann D, Raymick J, Sarkar S, Paule MG, Lahiri DK, Dumas M, Bell-Cohen A, Schmued LC.

Curr Alzheimer Res. 2014 Mar;11(3):299-308.

PMID:
24552157
20.

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.

Rijal Upadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamaguchi H, Fändrich M, Walter J, Thal DR.

Brain. 2014 Mar;137(Pt 3):887-903. doi: 10.1093/brain/awt362. Epub 2014 Feb 10.

PMID:
24519982

Supplemental Content

Support Center